好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Acceleration of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly with ?-Amyloidosis
Aging and Dementia
S04 - (-)
006
The appearance of [szlig]-amyloid and brain injury biomarkers in cognitively normal persons each confer risk for the future development of cognitive impairment due to Alzheimer's disease (AD), but their interaction is poorly understood.
Participants were 191 cognitively normal (CN) persons in the Mayo Clinic Study of Aging who underwent MR, FDG PET and PiB PET imaging at least twice >1 year apart. Subjects were grouped according to the recommendations of the NIA-AA Preclinical AD criteria: ?-amyloidosis defined as PiB PET SUVr >1.5 alone or with brain injury defined as hippocampal atrophy or AD-like FDG hypometabolism. We also included MCI and dementia patients (n=26) from the Mayo Clinic Study of Aging or the Mayo Alzheimer Center who had comparable imaging and who all had PiB PET SUVr >1.5.
There were 25 CN subjects with both high PiB retention and low hippocampal volume or FDG hypometabolism (Preclinical AD stages 2+3); they had a greater rate of hippocampal volume loss compared to other CN subjects (p<0.01), a rate that was comparable to the MCI and dementia due to AD participants. The preclinical AD stages 2+3 subjects had low baseline FDG hypometabolism but did not show a greater rate of FDG hypometabolism. Higher rates of longitudinal decline in FDG occurred in subjects with MCI and, more so, dementia due to AD.
Higher rates of hippocampal volume loss occurred in CN individuals who had abnormal levels of both ?-amyloid and brain injury biomarkers at baseline compared to other CN participants with only one or no abnormal biomarker classes. Higher rates of FDG hypometabolism were not evident in our CN participants and might be a later event in the AD pathological cascade.
Authors/Disclosures
David S. Knopman, MD, FAAN (Mayo Clinic)
PRESENTER 		Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Robert B. Davis, RN, MS, MSN, FNP (UVA - Neurology) No disclosure on file
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
No disclosure on file
Vitor Pereira-Mendes No disclosure on file
Stephen Weigand Stephen Weigand has nothing to disclose.
Prashanthi Vemuri, PhD (Mayo Clinic) The institution of Dr. Vemuri has received research support from NIH.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Kejal Kantarci, MD (Mayo Clinic) The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF.
Matthew Senjem (Mayo Clinic) Matthew Senjem has received stock or an ownership interest from Align Technology, Inc.. Matthew Senjem has received stock or an ownership interest from Inovio Biomedical Corp.. Matthew Senjem has received stock or an ownership interest from Johnson & Johnson. Matthew Senjem has received stock or an ownership interest from Mesa Laboratories, Inc.. Matthew Senjem has received stock or an ownership interest from Nvidia Inc.. Matthew Senjem has received stock or an ownership interest from LHC Group, Inc.. Matthew Senjem has received stock or an ownership interest from Natus Medical Incorporated. Matthew Senjem has received stock or an ownership interest from Varex Imaging Corporation. Matthew Senjem has received personal compensation in the range of $100,000-$499,999 for serving as a IT Technical Specialist II with Mayo Clinic.
Jeffery Gunter (Mayo Clinic and Foundation) The institution of Jeffery Gunter has received research support from NIH. Jeffery Gunter has received intellectual property interests from a discovery or technology relating to health care.
Michelle Mielke No disclosure on file
Rosebud O. Roberts, MD (Mayo Clinic) No disclosure on file
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.